[Heterogeneity of antibodies blocking the binding of bungarotoxin to the acetylcholine receptor in myasthenia].
Inhibitory effect of myasthenic patients antibodies on alpha-bungarotoxin binding to the human acetylcholine receptor has been demonstrated by radioimmunoassay. By using decamethonium, an acetylcholine agonist, we have shown the existence of two antibody sub-groups reacting with the toxin-binding site: one sub-group is represented by antibodies which block the binding directly, the other by antibodies that inhibit the binding, only in the presence of decamethonium.
D000906:Antibodies / Q000032:analysis*; D002038:Bungarotoxins / Q000378:metabolism*; D003650:Decamethonium Compounds; D006801:Humans; D007700:Kinetics; D009157:Myasthenia Gravis / Q000276:immunology*; D011863:Radioimmunoassay; D011950:Receptors, Cholinergic / Q000276:immunology* / Q000378:metabolism
D000906:Antibodies; D002038:Bungarotoxins; D003650:Decamethonium Compounds; D011950:Receptors, Cholinergic; C033019:decamethonium
Hétérogénéité des anticorps bloquant la fixation de la bungaro-toxine sur le récepteur de l'acétylcholine dans la myasthénie.